Drug Trial Radar · NCT01985334
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,389
Actual
Start
Feb 14, 2014
Primary completion
Apr 29, 2016
Study completion Apr 29, 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their current COPD therapy. This study aims to provide data on how non-exacerbating, but still symptomatic patients with moderate COPD switching from their current COPD treatment to glycopyrronium bromide or indacaterol maleate and glycopyrronium bromide FDC maintain or improve their symptoms. Another purpose of this study is to increase awareness and usage of validated COPD symptoms tools and dyspnea questionnaires in order to facilitate clinical assessment and improve early diagnosis of symptomatic patients.
Conditions
- COPD
Interventions
GlycopyrroniumDrug
Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
SABADrug
Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
LABADrug
Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
Indacaterol maleate and glycopyrronium bromideDrug
Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
LAMADrug
Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
SAMADrug
Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
ICSDrug
Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)Time frame: Week 12 (Visit 4)
- Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Week 12 (Visit 4)
- Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDCTime frame: Week 12 (Visit 4)
- Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Week 12 (Visit 4)
- Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)Time frame: Day 1 (baseline) and week 12
- Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Day 1 (baseline) and week 12
- Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDCTime frame: Day 1 (baseline) and week 12
- Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)Time frame: Day 1 (baseline) and week 12
Locations
542 sites in 23 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Amstetten, Austria
Novartis Investigative Site
Feldkirch, Austria
Novartis Investigative Site
Hallein, Austria
Novartis Investigative Site
Kirchdorf an der Krems, Austria
Novartis Investigative Site
Leoben, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Perg, Austria
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Wels, Austria
Novartis Investigative Site
Antwerp, Belgium
Novartis Investigative Site
Balen, Belgium
Novartis Investigative Site
Braine-l'Alleud, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Éghezée, Belgium
Novartis Investigative Site
Erpent, Belgium
Novartis Investigative Site
Geraardsbergen, Belgium
Novartis Investigative Site
Gilly, Belgium
Novartis Investigative Site
Halen, Belgium
Novartis Investigative Site
Hasselt, Belgium
Novartis Investigative Site
Heusy, Belgium
Novartis Investigative Site
Ieper, Belgium
Novartis Investigative Site
Knokke-Heist, Belgium
Novartis Investigative Site
Lebbeke, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Maaseik, Belgium
Novartis Investigative Site
Malmedy, Belgium
Novartis Investigative Site
Mechelen, Belgium
Novartis Investigative Site
Melsbroek, Belgium
Novartis Investigative Site
Merksem, Belgium
Novartis Investigative Site
Montegnée, Belgium
Novartis Investigative Site
Natoye, Belgium
Novartis Investigative Site
Paal-Beringen, Belgium
Novartis Investigative Site
Ronse, Belgium
Novartis Investigative Site
Saint-Médard, Belgium
Novartis Investigative Site
Seraing, Belgium
Novartis Investigative Site
Tournai, Belgium
Novartis Investigative Site
Verviers, Belgium
Novartis Investigative Site
Vilvoorde, Belgium
Showing 40 of 542 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.